Analyzing Phase 1/1b Results for Revolution Medicines' (RVMD) RMC-6236 in PDAC and NSCLC

Scheduled for:Mar 30, 2025 8:00 PM EDT

Call Duration:30 minutes

Desired Expert

An oncologist specializing in targeted therapies for RAS-driven cancers with experience in clinical trials and an understanding of the challenges in treating PDAC, NSCLC, and other RAS-mutant solid tumors.

Interview Goal

This interview will explore updated clinical data for RMC-6236, a RAS(ON) multi-selective inhibitor, in metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The discussion will highlight efficacy, safety, and the potential of RMC-6236 in combination therapies, alongside future developments in RAS-addicted cancer treatment.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.